• Doximity reported quarterly revenue of US$174.54 million and net income of US$34.73 million for the period ended September 30, 2026, alongside revenue guidance of US$678 million to US$683 million for fiscal 2027.
• The launch of DoseCheck, which adds a rule based safety layer to Doximity Ask and has cut AI dosing errors by more than 99%, highlights management’s focus on clinically trusted AI tools that can matter to both physicians and healthcare customers.
• We will now look at how Doximity's DoseCheck rollout and AI adoption could influence the broader investment narrative around the business.

Capitalize on the rise of clinically focused AI by scanning a hand-picked set of 37 healthcare AI stocks that, like Doximity, are leaning into safety, workflows, and real physician adoption.

Doximity Investment Narrative Recap

To own Doximity, you need to believe its physician network and workflow tools can keep attracting real clinical usage and that this usage ultimately supports pharma marketing and hospital software budgets. According to Dc12, an investor in the Simply Wall St Community, the draw is high physician viewership and respected clinical tools, which recent AI launches appear to support.

The latest quarter shows revenue of US$174.54 million and net income of US$34.73 million, while guidance calls for US$678 million to US$683 million in fiscal 2027 revenue. The key near term catalyst is whether expanding AI workflows convert to advertiser and health system spend. Margin pressure and earnings volatility remain the biggest current risk.

The DoseCheck launch looks most relevant to the current story because it targets one of the highest risk AI use cases, medication dosing, and Doximity claims a more than 99% reduction in AI dosing errors. That fits Dc12’s view that the platform has strong physician buy in and increasingly credible clinical tools that practicing doctors actually use.

From an investor lens, DoseCheck sits right on the line between catalyst and execution test. It could support deeper health system adoption of Doximity Ask and related Clinical AI Suite products, which may matter for converting usage into revenue within the fiscal 2027 guidance range. The operational watchpoint is whether this safety focused AI approach offsets margin compression from higher compute and product investment.

Dc12’s narrative arrives at a fair value of US$33.70 per share by combining a 17.0% annual revenue growth assumption with a future profit margin of 30.4%. This view is anchored in the belief that Doximity’s physician audience and clinical AI tools can be monetized more efficiently over time.

Uncover why Doximity's fair value is currently aligned with its price.

Exploring Other Perspectives

One alternate view fixates on profit pressure. The most bearish analysts were assuming revenue of about US$779.9 million and earnings of roughly US$156.2 million by 2029, with profit margins shrinking. That pre-news stance treats Doximity’s AI spend and governance issues as bigger threats, which could shift as DoseCheck and fresh guidance get digested.

Explore 4 other Doximity fair value estimates, including one that suggests as much as 46% downside from the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Doximity research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Doximity. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Doximity's overall financial health at a glance.

Looking For More Investment Ideas Beyond Doximity?

If the Doximity story has you thinking about where else clinically focused or resilient business models might show up in your portfolio, it can help to scan a broader opportunity set before making any moves.

• For investors who want a margin of safety backed by fundamentals, start with a 32 high quality undervalued stocks that screens for quality and price discipline in one place.
• If capital preservation and steadier profiles matter most to you, a 30 resilient stocks with low risk scores can surface companies with more resilient characteristics and fewer red flags.
• When the goal is to balance stability with growth potential, a curated list of solid balance sheet and fundamentals (23 results) can highlight businesses with stronger finances that still leave room for potential opportunities.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.